Compare Mesoblast Limited (MESO) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs First Trust Cloud Computing ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while First Trust Cloud Computing ETF trades at $170.83 (market cap $3.47B). The key difference: First Trust Cloud Computing ETF is the larger of the two by market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and First Trust Cloud Computing ETF for 84 Days on average.
| MESO | SKYY | |
|---|---|---|
Market Cap | $1.75B | $3.47B |
Volume | 239,027 | 176,159 |
Sector | Health | — |
52-Week High | $20.96 | $171.01 |
52-Week Low | $13.19 | $104.16 |
Typical Hold Time | 14 Days | 84 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
SKYY, the First Trust Cloud Computing ETF, trades at $170.78, down 0.13% on the day but near its 52-week high. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The fund provides diversified exposure to the cloud computing sector, benefiting from AI adoption and digital transformation trends. Recent news highlights a new 52-week high and institutional activity, reflecting positive momentum.
The outlook for SKYY is favorable, driven by secular growth in cloud infrastructure and AI demand. Key opportunities include exposure to hyperscaler capex and data center investments without heavy concentration in mega-cap tech. Risks involve sector volatility, competitive pressures, and macroeconomic sensitivity. Analyst sentiment is constructive, with the ETF positioned to capitalize on long-term technology shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
